Biliary tract carcinoma: from clinical classification to molecular classification

doi:10.16139/j.1007-9610.2021.02.002

Abstract

CLC Number:

R735.8

ZHANG Rui, SU Jingbo, ZHANG Jian, GENG zhimin. Biliary tract carcinoma: from clinical classification to molecular classification[J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 97-102.

References 43

[1]	Personeni N, Lleo A, Pressiani T, et al. Biliary tract cancers: molecular heterogeneity and new treatment options[J]. Cancers(Basel), 2020, 12(11):3370.
[2]	李茂岚, 刘颖斌. 胆道恶性肿瘤临床研究进展与展望[J]. 中国实用外科杂志, 2020, 40(2):167-170.
[3]	Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5):594-599.
[4]	Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part Ⅲ: liver, biliary tract, and pancreas[J]. Gastroenterology, 2009, 136(4):1134-1144. doi: 10.1053/j.gastro.2009.02.038 pmid: 19245868
[5]	Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and ma-nagement[J]. Nat Rev Gastro Hepat, 2020, 17(9):557-588.
[6]	Lamarca A, Barriuso J, Mcnamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer[J]. J Hepatol, 2020, 73(1):170-185. doi: S0168-8278(20)30165-3 pmid: 32171892
[7]	Kelley RK, Bridgewater J, Gores GJ, et al. Systemic the-rapies for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2):353-363. doi: S0168-8278(19)30611-7 pmid: 31954497
[8]	任泰, 李永盛, 耿亚军, 等. 中国2010—2017年胆囊癌治疗模式及预后分析[J]. 中华外科杂志, 2020, 58(9):697-706.
[9]	李秉璐, 吴昕. 国内外有关肝内胆管癌分型分期解读[J]. 中国实用外科杂志, 2020, 40(6):656-660.
[10]	Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma[J]. Ann Surg, 1992, 215(1):31-38. pmid: 1309988
[11]	Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma - patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system[J]. Ann Surg, 1998, 228(3):385-392. pmid: 9742921
[12]	Deoliveira ML, Schulick RD, Nimura Y, et al. New sta-ging system and a registry for perihilar cholangiocarcinoma[J]. Hepatology, 2011, 53(4):1363-1371. doi: 10.1002/hep.24227 pmid: 21480336
[13]	Sasaki R, Murata S, Oda T, et al. Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma[J]. Langenbecks Arch Surg, 2010, 395(6):615-623.
[14]	Gazzaniga GM, Faggioni A, Filauro M. Surgical treatment of proximal bile duct tumors[J]. Int Surg, 1985, 70(1):45-48. pmid: 2410390
[15]	Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer[M]. 2th. Japan: Kanehara, 2003:99-100.
[16]	Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification[J]. J Hepatobiliary Pancreat Surg, 2003, 10(4):288-291.
[17]	季林华, 赵刚, 吴志勇. 肝内胆管癌分型分期与治疗[J]. 中华消化外科杂志, 2010, 9(3):193-196.
[18]	张东, 耿智敏, 陈晨, 等. 胆囊癌的临床分型和预后关系初步分析: 多中心回顾性临床研究[J]. 中华外科杂志, 2019, 57(4):258-264.
[19]	Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance[J]. Histopa-thology, 2017, 70(3):423-434.
[20]	Shibata T, Arai Y, Totoki Y. Molecular genomic landscapes of hepatobiliary cancer[J]. Cancer Sci, 2018, 109(5):1282-1291.
[21]	Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010. doi: 10.1038/ng.3375 pmid: 26258846
[22]	Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management[J]. Cancer, 2016, 122(24):3838-3847.
[23]	Nepal C, O′rourke CJ, Oliveira DVNP, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma[J]. Hepatology, 2018, 68(3):949-963.
[24]	Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer[J]. Nat Rev Dis Primers, 2019, 5(1):66. doi: 10.1038/s41572-019-0111-2 pmid: 31548545
[25]	Hoshida Y, Nijman SMB, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(18):7385-7392. doi: 10.1158/0008-5472.CAN-09-1089 pmid: 19723656
[26]	Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nat Med, 2015, 21(11):1350-1356. doi: 10.1038/nm.3967 pmid: 26457759
[27]	Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy[J]. Nat Med, 2011, 17(4):500-503. doi: 10.1038/nm.2344 pmid: 21460848
[28]	Sia D, Hoshida Y, Villanueva A, et al. Integrative molecu-lar analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4):829-840.
[29]	Rhee H, Ko JE, Chung T, et al. Transcriptomic and histopathological analysis of cholangiolocellular differentia-tion trait in intrahepatic cholangiocarcinoma[J]. Liver Int, 2018, 38(1):113-124.
[30]	Ahn KS, O′brien D, Kang YN, et al. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative mole-cular-clinical analysis and potential targeted approach[J]. Hepatol Int, 2019, 13(4):490-500.
[31]	Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(2):315-327.
[32]	Son KH, Ahn CB, Kim HJ, et al. Quantitative proteomic analysis of bile in extrahepatic cholangiocarcinoma patients[J]. J Cancer, 2020, 11(14):4073-4080.
[33]	Kotawong K, Chaijaroenkul W, Roytrakul S, et al. Proteomics analysis for identification of potential cell signa-ling pathways and protein targets of actions of atractylodin and beta-eudesmol against cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2020, 21(3):621-628.
[34]	Darby IA, Vuillier-Devillers K, Pinault E, et al. Proteo-mic analysis of differentially expressed proteins in peri-pheral cholangiocarcinoma[J]. Cancer Microenviron, 2010, 4(1):73-91.
[35]	Yu WL, Yu GZ, Dong H, et al. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma[J]. J Gastroenterol, 2020, 55(12):1171-1182.
[36]	Chang TT, Ho CH. Plasma proteome atlas for differentia-ting tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma[J]. PloS One, 2020, 15(8):e0238251.
[37]	Urman JM, Herranz JM, Uriarte I, et al. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach[J]. Cancers(Basel), 2020, 12(6):1644.
[38]	Liang Q, Liu H, Zhang TY, et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma[J]. Mol Biosyst, 2016, 12(2):334-340. doi: 10.1039/c5mb00572h pmid: 26646623
[39]	刘立果, 张一鉴, 王许安, 等. 免疫治疗在胆道恶性肿瘤中的应用进展[J]. 中华外科杂志, 2021, 59(2):158-161.
[40]	Job S, Rapoud D, Santos AD, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3):965-981.
[41]	Tamma R, Annese T, Ruggieri S, et al. Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma[J]. Eur J Clin Invest, 2019, 49(5):e13087.
[42]	Nepal C, Zhu B, O′rourke CJ, et al. Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes[J]. J Hepatol, 2020, S0168-8278(20):33820-33824.
[43]	Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma[J]. Cancer Discov, 2017, 7(10):1116-1135. doi: 10.1158/2159-8290.CD-17-0368 pmid: 28667006

Biliary tract carcinoma: from clinical classification to molecular classification

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 43

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Hongzhan, ZHANG Kai. Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320.
[2]	ZHU Siwei, YIN Xinmin. Laparoscopic radical resection of hilar cholangiocarcinoma: current status and considerations [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 100-103.
[3]	LI Xiangcheng, CHEN Yananlan, LI Changxian. Vascular reconstruction in radical resection for hilar cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 104-109.
[4]	XING Ying, CHENG Shi. Neoadjuvant therapy for gallbladder cancer: current status and challenge [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 110-114.
[5]	LUO Fangxiu, MA Qianchen, YUAN Fei. The fifth edition of WHO classification of digestive system tumors: update and progress on biliary system tumors [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 124-131.
[6]	WANG Yuanjiang, ZOU Hao. Clinical study on comprehensive treatment of gallbladder cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 171-176.
[7]	CHEN Xuanwu, YANG Chuanyu, JIANG Minjie, DU Weidong. Progress of study on gallbladder adenomyomatosis: pathogenesis, diagnosis and treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 87-90.
[8]	WANG Kaiyu, WANG Liang, SHU Bin, ZHANG Yuewei, HUANG Xin, GE Xiaqing, XIAO Ming, ZHANG Qijia, YAN Zhe, SONG Yan, XIANG Canhong. Radical resection of hilar cholangiocarcinoma combined with left hepatectomy and resection of ventral segment of right anterior sector: one case report [J]. Journal of Surgery Concepts & Practice, 2021, 26(05): 441-444.
[9]	WU Wenta, LI Wei, CAO Yijun. Diagnosis and treatment of xanthogranulomatous cholecystitis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 271-274.
[10]	WU Gang, CAI Duan. Surgical treatment of gallbladder polyp: controversy and strategy [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 107-110.
[11]	LI Jingdong, ZHU Jianjiao, ZHANG Lixin, XIONG yongfu. Laparoscopic radical resection of hilar cholangiocarcinoma: controversy and consensus* [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 115-119.
[12]	CHEN Danlei, SHAO Chenghao. Controversy in minimally invasive treatment of distal cholangiocarcinoma and key technical points [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 120-123.
[13]	WANG Chong, CHENG Shi. Intrahepatic cholangiocarcinoma: interpretation of expert consensus and guideline from domestic and abroad [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 124-129.
[14]	LIU Hongzhi, LIN Ziguo, HUANG Jianlong, ZHOU Weiping, CHENG Zhangjun, LOU Jianying, ZHENG Shuguo, BI Xinyu, WANG Jianming, GUO Wei, LI Fuyu, WANG Jian, ZHENG Yamin, LI Jingdong, CHENG Shi, LIU Jingfeng, ZENG Yongyi. Effect of surgical margin width on prognosis in patients with single intrahepatic cholangiocarcinoma from a multicenter study [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 130-137.
[15]	SI Anfeng, LEI Zhengqing, YANG Pinghua, JIANG Tao, WANG Xuan, CHENG Zhangjun. Effectiveness of postoperative transarterial chemoembolization for huge intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 138-143.